NorthX Biologics secures significant growth investment from Signet Healthcare Partners — Signet Healthcare Partners
Summary
It serves a global customer base of biopharmaceutical and biotech companies, from early development through commercial GMP manufacturing.The investment was made through a new issue of shares. NorthX Biologics differentiated capabilities across microbial and mammalian manufacturing systems, nucleic acids, advanced therapies and aseptic fill-finish are a strong match with the evolving needs of the global biopharma market. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Fleries active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders.